Catalyst Pharmaceuticals, Inc.
CPRX
Rang in Aktien
#4177
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Aktienkurs
$31.49
Zuletzt synchronisiert: 2026-07-21
Marktkapitalisierung
$3.85B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
49.88%
Land
US
Handel Catalyst Pharmaceuticals, Inc. (CPRX)
Kategorie
Healthcare
Umsatz von Catalyst Pharmaceuticals, Inc. (CPRX)
Umsatz im Mar 2026 TTM: $596.96M
Laut den aktuellen Finanzberichten von Catalyst Pharmaceuticals, Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $596.96M. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $398.20M eine Steigerung gegenüber dem Umsatz im Jahr 2022, der $214.20M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Catalyst Pharmaceuticals, Inc. von 2002 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $596.96M | 21.40% |
| 2024 | $491.73M | 23.49% |
| 2023 | $398.20M | 85.90% |
| 2022 | $214.20M | 52.10% |
| 2021 | $140.83M | 18.27% |
| 2020 | $119.07M | 16.39% |
| 2019 | $102.31M | 20,361.20% |
| 2018 | $500.00K | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | -100.00% |
| 2010 | $488.96K | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 2,014.77% |
US
|
|
| $2.23B | 273.23% |
US
|
|
| $15.74B | 2,537.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 908.66% |
NL
|
